Cited 13 times in
Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재영 | - |
dc.date.accessioned | 2020-12-01T16:52:14Z | - |
dc.date.available | 2020-12-01T16:52:14Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180020 | - |
dc.description.abstract | Background/aims: Ghrelin agonists are emerging prokinetic agents for treating gastroparesis. Although recent clinical trials have demonstrated their efficacy in patients with diabetic gastroparesis (DG), the impact of such agents on symptoms and gastric dysmotility remains unclear. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of ghrelin agonists in patients with DG. Methods: A search of common electronic databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) was preformed, using keyword combinations that referenced ghrelin and DG and retrieving all eligible randomized controlled trials (RCTs) of ghrelin agonists versus placebo in patients with DG. The primary outcome measure was the change in patient-reported overall gastroparesis symptom scores. Secondary outcomes included the change in gastric emptying time, specific symptoms related to gastroparesis, and adverse events. A random-effects model was applied to all study outcomes. Heterogeneity among studies was determined by the chi-square test and I2 statistics. Results: We selected six RCTs of patients with DG (n=557) for meta-analysis. Ghrelin agonist administration (vs placebo) significantly improved overall gastroparesis symptoms (standardized mean difference, -0.34; 95% confidence interval, -0.56 to -0.13) and significantly improved symptoms related to gastroparesis, including nausea, vomiting, early satiety, and abdominal pain. Adverse events recorded for ghrelin agonists and placebo did not differ significantly. There was no significant heterogeneity among eligible studies. Conclusions: Compared with placebo, ghrelin agonists are effective and well-tolerated for the treatment of DG. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Editorial Office of Gut and Liver | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy and Safety of Ghrelin Agonists in Patients with Diabetic Gastroparesis: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung Wook Hong | - |
dc.contributor.googleauthor | Jaeyoung Chun | - |
dc.contributor.googleauthor | Jihye Kim | - |
dc.contributor.googleauthor | Jooyoung Lee | - |
dc.contributor.googleauthor | Hyun Jung Lee | - |
dc.contributor.googleauthor | Hyunsoo Chung | - |
dc.contributor.googleauthor | Soo-Jeong Cho | - |
dc.contributor.googleauthor | Jong Pil Im | - |
dc.contributor.googleauthor | Sang Gyun Kim | - |
dc.contributor.googleauthor | Joo Sung Kim | - |
dc.identifier.doi | 10.5009/gnl19103 | - |
dc.contributor.localId | A05701 | - |
dc.relation.journalcode | J00954 | - |
dc.identifier.eissn | 2005-1212 | - |
dc.identifier.pmid | 31816671 | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Gastroparesis | - |
dc.subject.keyword | Ghrelin | - |
dc.subject.keyword | Meta analysis | - |
dc.subject.keyword | Systematic review | - |
dc.contributor.alternativeName | Cheon, Jae Young | - |
dc.contributor.affiliatedAuthor | 천재영 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 589 | - |
dc.citation.endPage | 600 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, Vol.14(5) : 589-600, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.